Skip to content
Testing only — This site is not approved for clinical use. Do not use for patient care decisions.

Overview

What is Intranasal Dexmedetomidine?

Dexmedetomidine is a highly selective alpha-2 adrenoceptor agonist that produces anxiolysis, sedation, and mild analgesia. When administered intranasally, it is absorbed rapidly across the nasal mucosa and produces a calm, cooperative sedation suitable for children undergoing procedures or requiring premedication before anaesthesia.

Intranasal administration avoids the need for an intravenous cannula prior to the procedure — one of its primary advantages in paediatric practice.

Key Properties

PropertyDetail
Drug classAlpha-2 adrenoceptor agonist
RouteIntranasal via mucosal atomiser device (MAD)
Onset20–45 minutes
Duration60–120 minutes
Sedation qualityCalm, cooperative; child remains rousable
Respiratory depressionMinimal at standard doses
Anxiolytic effectYes — primary indication for premedication
Analgesic effectMild

Indications

Intranasal dexmedetomidine is used at MCH for:

  • Premedication before induction of general anaesthesia in anxious or uncooperative children
  • Procedural sedation for brief, minimally painful procedures (IV cannulation, wound care, dressing changes, suturing)
  • Imaging sedation — particularly MRI, where the child must remain still for an extended period
  • Anxiolysis before painful procedures where a cooperative child is preferred over deep sedation

Typical Age Range

Most evidence and experience is in children aged 6 months to 12 years. Use in infants <6 months or adolescents requires senior anaesthetist review.


Mechanism of Action

Alpha-2 agonism in the locus coeruleus produces sedation via a pathway resembling natural sleep. The child remains rousable and can usually be directed to cooperate with procedures. Unlike propofol or ketamine, dexmedetomidine does not cause significant respiratory depression or loss of protective airway reflexes at standard intranasal doses.


Advantages Over Other Agents

  • No needle required for administration — particularly valuable in needle-phobic children
  • Child remains calm and cooperative — can follow simple commands
  • Airway protective reflexes are preserved
  • Smooth transition to inhalational anaesthesia if used as premedication
  • Does not cause emergence agitation (may reduce it)
  • No significant respiratory depression at standard doses

Limitations

  • Onset is slow (20–45 min) — requires planning and timing
  • Not reliable for deep sedation — unsuitable for significantly painful procedures
  • Intranasal administration can cause transient nasal discomfort; a crying or uncooperative child may prevent adequate absorption
  • Bradycardia can occur — monitoring is required
  • Effect cannot be reversed pharmacologically